Management attributed the higher operating loss primarily to increased share-based compensation, business combination costs and the absence of government assistance. Research and development expenses rose 67% to $18.1 million, reflecting higher compensation, LM26 materials spending and staffing costs. Net loss reached $92.35 million, compared with net income of $31.08 million, partly reflecting financial instrument revaluation losses. Cash and cash equivalents totaled $105.6 million at September 30, with short-term investments of $35.3 million.